Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.
- DOI
- 10.1007/s12325-023-02719-3
- Published
- 2024-01-06
- Container
- Adv Ther
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s12325-023-02719-3,
title = {Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.},
author = {Kodjikian L and Arias Barquet L and Papp A and Kertes PJ and Midena E and Ernest J and Silva R and Schmelter T and Niesen T and Leal S.},
year = {2024},
journal = {Adv Ther},
doi = {10.1007/s12325-023-02719-3},
url = {https://doi.org/10.1007/s12325-023-02719-3}
}RIS
TY - JOUR TI - Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing. AU - Kodjikian L AU - Arias Barquet L AU - Papp A AU - Kertes PJ AU - Midena E AU - Ernest J AU - Silva R AU - Schmelter T AU - Niesen T AU - Leal S. PY - 2024 JO - Adv Ther DO - 10.1007/s12325-023-02719-3 UR - https://doi.org/10.1007/s12325-023-02719-3 ER -
APA
L, K., L, A. B., A, P., PJ, K., E, M., J, E., R, S., T, S., T, N., & S., L. (2024). Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing.. Adv Ther. https://doi.org/10.1007/s12325-023-02719-3
Source records
- europe-pmc · retrieved 2026-09-26T08:03:55.713Z
- hal · retrieved 2026-09-26T08:03:55.735Z